Molecular mechanisms regulating the hormone sensitivity of breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• Breast cancer is a heterogeneous disease, with ~70% of cases being estrogen receptor (ER)-positive.
• Endocrine therapy significantly improves outcomes for ER-positive breast cancer patients.
• Tumor resistance to endocrine therapy, both de novo and acquired, remains a clinical challenge.

Purpose of the Study:

• To elucidate the molecular mechanisms governing hormone sensitivity and resistance in ER-positive breast cancer.
• To investigate the role of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway in endocrine therapy resistance.
• To examine the function of the FOXA1 transcription factor in ER signaling and endocrine response.

Main Methods:

• This review synthesizes current research on signaling pathways and transcription factors involved in breast cancer hormone sensitivity.
• Focuses on the PI3K/Akt/mTOR pathway's role in mediating resistance to endocrine therapies.
• Analyzes the function of FOXA1 as a key regulator of ER activity and endocrine response.

Main Results:

• The PI3K/Akt/mTOR pathway is implicated in mediating resistance to various endocrine therapies for breast cancer.
• FOXA1 is identified as a critical determinant of ER function and the response to endocrine treatment.
• Emerging evidence suggests a connection between PI3K/Akt/mTOR-induced hormone resistance and FOXA1 activity.

Conclusions:

• Understanding the interplay between the PI3K/Akt/mTOR pathway and FOXA1 is crucial for improving endocrine therapy efficacy.
• Targeting these molecular mechanisms may offer strategies to overcome endocrine resistance in ER-positive breast cancer.
• Further research into these pathways can lead to novel therapeutic approaches for hormone-sensitive breast cancers.